All‐cause mortality · pulmonary hypertension in neonates
It is very uncertain whether sildenafil changes all‐cause mortality compared with active control (very low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
ICU mortality · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Interventions showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
It is very uncertain whether H2 receptor antagonists changes all‐cause mortality in ICU compared with antacids (very low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
All‐cause mortality · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
It is very uncertain whether band ligation changes all‐cause mortality compared with sham or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
All‐cause mortality at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review